Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)-Reference-Cited by-同舟云学术

Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Published:2023-01-09 Issue:4 Volume:58 Page:401-406
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Srour Micha^ORCID,Alsuliman Tamim,Labreuche Julien,Bulabois Claude-Eric,Chevallier Patrice,Daguindau Etienne,Forcade Edouard^ORCID,François Sylvie,Guillerm Gaelle,Coiteux Valerie,Turlure Pascal,Beguin Yves,Yakoub-Agha Ibrahim,Magro Leonardo

Funder

Novartis

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-022-01898-x.pdf

Reference36 articles.

1. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40,000 transplants annually. Bone Marrow Transpl. 2016;51:786–92.

2. Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al. Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation – A Report from CIBMTR. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2015;21:266–74.

3. Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers MED, Cutler CS, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011;117:6714–20.